Mr Mfazo Hove
Mr Hove
MBChB MD FRCOphth CertLRS
Consultant Ophthalmic Surgeon | Founder & Lead Surgeon, Blue Fin Vision®
Fellow of the Royal College of Ophthalmologists | Key Opinion Leader, ZEISS Medical Technology
Mr Mfazo Hove MBChB MD FRCOphth CertLRS is a Consultant Ophthalmic Surgeon and Founder of Blue Fin Vision®, a leading consultant-led eye surgery group with locations across London and the South East. With more than 50,000 cataract, refractive and intraocular procedures performed – including over 24,000 in the last four years alone – he is widely recognised as one of the UK’s most experienced and consistent high-volume eye surgeons. His audited outcomes rank among the strongest nationally, with exceptionally low complication rates that consistently outperform published benchmarks.
Training, Qualifications & Fellowship Expertise
Mr Hove graduated with First-Class Honours in Medicine from the University of Liverpool. He commenced ophthalmology training at Eastbourne and St Thomas’ Hospital, London, where he obtained his MRCOphth.
He then completed 2.5 years at Moorfields Eye Hospital as a Cataract Research Fellow, earning an MD focused on multifocal intraocular lenses and refractive outcomes. He subsequently undertook Medical Retina, Cataract and Anterior Segment fellowships, gaining high-volume surgical exposure under internationally respected mentors.
He completed the North Thames Ophthalmology Training Programme, achieved FRCOphth, gained the Certificate in Laser Refractive Surgery (CertLRS), and was awarded his CCT, joining the GMC Specialist Register.
Current Roles, Training Responsibilities & Governance Leadership
Mr Hove previously held a Consultant Ophthalmologist post at the Western Eye Hospital (Imperial College Healthcare), where he also served as Lead for Eye Casualty.
He is now the Lead Consultant Ophthalmic Surgeon at Blue Fin Vision®, overseeing consultant-led standards, surgeon development, governance frameworks and multi-site consistency across the organisation.
As an Educational Supervisor at SpaMedica, he spends three days each week training registrars and early-career ophthalmologists within one of the UK’s highest-volume surgical environments. Many of his trainees have progressed into substantive consultant or specialist posts across the UK.
Mr Hove also contributes extensively to governance, serving on Medical Advisory Committees (MACs) at two private hospitals and acting as MAC representative for Freedom Vision at SpaMedica, supporting service quality, governance, training oversight and strategic development across multiple organisations.
Surgical Expertise & Innovation
Mr Hove specialises in:
- Cataract surgery
- Refractive lens exchange (RLE)
- Implantable Collamer Lens (ICL) surgery
- LASIK, SMILE and PRK/LASEK
- Presbyopia management
- Complex anterior segment surgery
He is known for his refined 4-Minute Phaco™ technique – a precision-based, low-trauma cataract approach that enhances safety and supports rapid visual recovery. Across tens of thousands of procedures, his complication rates remain significantly lower than national averages, reinforcing his reputation as one of the UK’s safest cataract surgeons.
Industry Leadership, KOL Status & International Speaking
Mr Hove is a Key Opinion Leader (KOL) for ZEISS Medical Technology, recognised for his expertise in cataract and refractive surgery, surgical optimisation and consultant-led models of care. He presents internationally at major ophthalmic congresses, sharing insights on refractive outcomes, surgical standardisation, training methodologies and modern presbyopia management.
Recognition & Reputation
Mr Hove is listed in the Spear’s 500 Health & Wellness Index 2025 as a Top Recommended Ophthalmic Surgeon and features in the Tatler Address Book 2026 for excellence in cataract, lens replacement and laser eye surgery.
Blue Fin Vision® has received consecutive Doctify Outstanding Patient Care Awards (2024 & 2025), reflecting its commitment to exceptional clinical outcomes, patient experience and consultant-led care.
Clinical Philosophy
Mr Hove founded Blue Fin Vision® to deliver modern, personalised and outcome-driven ophthalmic care defined by precision diagnostics, transparent communication and surgeon-led decision-making. His ethos ensures every patient receives individualised treatment aligned with their long-term visual goals.
Surgery & Treatments
Mr Hove provides a comprehensive range of surgical and non-surgical treatments to correct vision, manage eye disease, improve eyelid function, and rejuvenate the eye area.
He assesses, diagnoses, manages, and treats a wide spectrum of eye conditions, including:
- Refractive vision problems (short-sightedness, long-sightedness, astigmatism, and presbyopia)
- Diabetic eye disease and macular degeneration
- Glaucoma
- Dry eye and ocular surface disease
- Post-cataract and retinal complications
- Medical and surgical retinal (vitreoretinal) conditions
- Eye floaters (including YAG vitreolysis laser treatment)
His surgical expertise encompasses:
- Laser eye surgery (LASIK, PRK, LASEK, SMILE, PRESBYOND©, PresbyMAX©)
- Lens procedures including cataract surgery, refractive lens exchange, ICL surgery, and YAG laser capsulotomy
- He is widely recognised for his refined “4-Minute Phaco” technique, a precision-based, low-trauma approach that enhances safety and supports rapid visual recovery.
- Eyelid and oculoplastic surgery such as blepharoplasty, ptosis repair, entropion/ectropion correction, chalazion removal, and xanthelasma removal
- Ocular surface surgery including pterygium, pinguecula, and conjunctival naevus removal.
Recognition & Clinical Excellence
Mr Hove – Spear’s 500 Top Recommended Ophthalmic Surgeon 2025. This distinction places him at the highest tier awarded to any ophthalmologist in the Index, reflecting peer validation, patient testimony, and documented surgical outcomes. Mr Hove is currently the highest-ranked ophthalmologist in this prestigious benchmark of private client excellence.
As Consultant Ophthalmologist and Founder of Blue Fin Vision®, he is also featured in the Tatler Address Book 2026, which celebrates the UK’s most trusted eye surgeons. His inclusion highlights Blue Fin Vision®’s five-star patient feedback, published surgical outcomes, and premium, surgeon-led care across all locations.
With over 530 verified five-star reviews on Doctify and consecutive Outstanding Patient Care Awards in both 2024 and 2025, Mr Hove has established Blue Fin Vision® as a benchmark for patient-centred medicine. This remarkable consistency of patient satisfaction and independently verified excellence distinguishes Blue Fin Vision® in the UK’s private ophthalmology sector.
Professional Memberships
Medical Advisory Committee Positions
- Freedom Vision Medical Advisory Committee
- Phoenix Hospital Chelmsford Medical Advisory Committee
- One Hatfield Hospital Medical Advisory Committee
Industry Consultancy
Mr Hove is a paid consultant for Carl Zeiss Meditec AG, contributing clinical insights into lens-based surgery and presenting his findings at professional conferences.
Mr Hove’s Posterior Capsular Rupture (PCR) Data
Posterior capsular rupture (PCR) is the most common and the most important intraoperative complication during cataract surgery. When it occurs, there is:
6 fold risk of noticeably worse vision
20 fold risk of post cataract retinal detachment
17 fold risk of severe bleeding into the eye during surgery
7 fold risk of post-operative infection (endophthalmitis).
Although PCR is occasionally unavoidable, it is generally accepted as an indicator of surgical quality.
Mr Hove’s commitment to transparency extends to publicly available surgical outcome data. His Posterior Capsule Rupture (PCR) rates, as recorded in the National Ophthalmology Database, demonstrate exceptional surgical quality that consistently exceeds national benchmarks, reinforcing his reputation as one of the UK’s safest and most consistent cataract surgeons.
National Ophthalmology Database: Data showing percentage without PCR
| Year | National | Mr Hove |
Number of Operations |
Within Limits |
|---|---|---|---|---|
|
2024 – 25 |
* |
99.80% |
5600 |
|
|
2023 – 24 |
* |
99.64% |
6159 |
|
|
2022 – 23 |
98.9% |
99.75% |
7279 |
|
|
2021 – 22 |
98.9% |
99.73% |
6271 |
|
*Data from the National Ophthalmology Database is not currently available for 2023 – 2025.
